Abstract
7604 Background: Access to new oncology treatments for non-small-cell lung cancer (NSCLC) could be expedited if progression free survival (PFS) was accepted by payers as a valid endpoint predictive for overall survival (OS). We investigated the relationship between PFS and OS in advanced NSCLC, which has previously been limited by available data. Methods: A systematic review of the published literature was conducted (1988 to August 2011; Medline/Embase/Cochrane). Identified studies were assessed against the following criteria for inclusion in the analysis: randomised design; NSCLC; advanced disease (Stage IIIb or IV); pharmacological treatment in 2 or more groups; reported outcomes included median OS and median PFS. For each pair of treatment groups compared, the median OS difference and the median PFS difference were calculated. The data were analysed with locally weighted least squares regression (LOWESS) to validate the linear relationship. Unweighted and weighted linear regression was used to test the significance of the relationship between OS difference and PFS difference. Results: A total of 124 clinical trials, with 40,568 patients, were included in the analysis. The studies ranged from middle aged cohorts to the elderly. Median performance status (ECOG/WHO) was 1. 70% of studies were first line and therapy type was predominantly chemotherapy (57%). 19 studies (15%) reported use of crossover or rescue therapy. Weighted linear regression demonstrated a highly significant linear relationship between OS difference and PFS difference (Table). The results suggest that a 1 month difference in PFS is associated with approximately 1.3 months difference in OS. Conclusions: Analysis of NSCLC trials showed the treatment effect on PFS was predictive of the treatment effect on OS. With increased use of multiple lines of treatment and crossover/rescue therapy in new NSCLC trials OS differences are frequently confounded, making PFS an important outcome for health care decision making. [Table: see text]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.